Eli Lil­ly CEO David Ricks talks Chi­na, AI, and phar­ma's next 'gold­en er­a' af­ter obe­si­ty

NEW YORK — Eli Lil­ly CEO David Ricks shared his view from the phar­ma in­dus­try’s peak in an hour­long con­ver­sa­tion Tues­day with the Eco­nom­ic Club of New York.

Ricks weighed in on every­thing from Alzheimer’s and AI to Chi­na ten­sions and the fu­ture of di­rect-to-con­sumer drug sales. Of course, there was al­so no avoid­ing the key dri­ver of Lil­ly’s in­dus­try-lead­ing pole po­si­tion: its megablock­buster obe­si­ty drugs. Here’s how the CEO of the drug­mak­er now val­ued at $716 bil­lion — more than the bell­wethers John­son & John­son and Mer­ck com­bined — sees the state of the in­dus­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER